Literature DB >> 15510204

Single-agent thalidomide for treatment of first relapse following high-dose chemotherapy in patients with multiple myeloma.

R Fenk, B Hoyer, U Steidl, M Kondakci, T Graef, R Heuk, L Ruf, C Strupp, F Neumann, U-P Rohr, B Hildebrandt, R Haas, G Kobbe.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15510204     DOI： 10.1038/sj.leu.2403564

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  2 in total

1.  Activity of 129 single-agent drugs in 228 phase I and II clinical trials in multiple myeloma.

Authors:  K Martin Kortuem; Kaitlyn Zidich; Steven R Schuster; Meaghan L Khan; Victor H Jimenez-Zepeda; Joseph R Mikhael; Rafael Fonseca; A Keith Stewart
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-12-28

2.  Internal ribosome entry site of bFGF is the target of thalidomide for IMiDs development in multiple myeloma.

Authors:  I-Chia Lien; Lin-Yea Horng; Pei-Lun Hsu; Chia-Ling Wu; Hui-Ching Sung; Rong-Tsun Wu
Journal:  Genes Cancer       Date:  2014-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.